European Journal of Nutrition

, Volume 51, Issue 4, pp 389–398

Does equol production determine soy endocrine effects?

  • Dana Shor
  • Thozhukat Sathyapalan
  • Stephen L. Atkin
  • Natalie J. Thatcher
Review

DOI: 10.1007/s00394-012-0331-7

Cite this article as:
Shor, D., Sathyapalan, T., Atkin, S.L. et al. Eur J Nutr (2012) 51: 389. doi:10.1007/s00394-012-0331-7

Abstract

Isoflavones, a group of phytoestrogens, are selective oestrogen receptor (ER) modulators. They may positively impact endocrine-related conditions but the current evidence is sparse. Equol, a non-steroidal oestrogen, is produced by the metabolism of the isoflavone daidzein by intestinal bacteria. In Western countries, 30–50% of individuals metabolize daidzein into equol and are known as equol producers. Equol production may be the source of benefit from isoflavones in endocrine disease.

Keywords

EquolPhytoestrogenIsoflavoneSoyCardiovascular diseaseOsteoporosisBreast cancer

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Dana Shor
    • 1
  • Thozhukat Sathyapalan
    • 2
    • 4
  • Stephen L. Atkin
    • 2
  • Natalie J. Thatcher
    • 3
  1. 1.Hull York Medical SchoolHullUK
  2. 2.Department of Diabetes and EndocrinologyHull York Medical SchoolHullUK
  3. 3.Food Standards AgencyLondonUK
  4. 4.Michael White Diabetes CentreHullUK